Healthcare Resource Utilization and Associated Costs in New Users of Empagliflozin versus DPP-4 Inhibitors and GLP-1 Agonists: A Comparative Analysis Based on Retrospective Real-World Data from German Sickness Funds

• Main Authors: Wilke T (Author), Picker N (Author), Müller S (Author), Stürmlinger A (Author), Deiters B (Author), Dittmar A (Author), Aberle J (Author), Gabler M (Author)
• Format: Book
• Published: Dove Medical Press, 2022-05-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Thomas Wilke,1 Nils Picker,2 Sabrina Müller,2 Anna Stürmlinger,3 Barthold Deiters,4 Axel Dittmar,1 Jens Aberle,5 Maximilian Gabler3 1IPAM e.V., Wismar, Germany; 2Ingress-Health HWM GmbH, Wismar, Germany; 3Boehringer Ingelheim Pharma GmbH & Co.KG, Ingelheim, Germany; 4GWQ ServicePlus AG, Düsseldo...